Profile data is unavailable for this security.
About the company
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
- Revenue in USD (TTM)0.00
- Net income in USD-21.14m
- Incorporated2020
- Employees29.00
- LocationGain Therapeutics Inc4800 Hampden Lane, Suite 200BETHESDA 20814United StatesUSA
- Phone+1 (301) 500-1556
- Fax+1 (302) 655-5049
- Websitehttps://www.gaintherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hcw Biologics Inc | 3.93m | -27.39m | 41.98m | 45.00 | -- | 4.80 | -- | 10.69 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -25.65m | 42.27m | 2.00 | -- | -- | -- | -- | -2.06 | -2.06 | 0.00 | -1.54 | 0.00 | -- | -- | -- | -200.56 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Benson Hill Inc | 359.83m | -132.72m | 42.61m | 270.00 | -- | 0.6332 | -- | 0.1184 | -0.7033 | -0.7082 | 1.90 | 0.3174 | 1.13 | 9.80 | 20.67 | 1,332,689.00 | -41.85 | -- | -49.16 | -- | 5.38 | 3.18 | -36.88 | -40.73 | 2.02 | -2.12 | 0.183 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 42.72m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| NextCure Inc | 0.00 | -63.73m | 43.36m | 82.00 | -- | 0.4367 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Gain Therapeutics Inc | 0.00 | -21.14m | 43.69m | 29.00 | -- | 5.05 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 44.08m | 23.00 | -- | -- | -- | 15.65 | -0.3175 | -0.3175 | 0.0308 | -0.1094 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Incannex Healthcare Inc | -100.00bn | -100.00bn | 44.13m | -- | -- | 3.12 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Movano Inc | 852.00k | -27.91m | 44.32m | 30.00 | -- | -- | -- | 52.02 | -0.5593 | -0.5593 | 0.0168 | -0.0263 | 0.0779 | -- | 2.12 | 28,400.00 | -254.99 | -151.50 | -559.26 | -188.58 | -42.61 | -- | -3,275.47 | -- | 0.5147 | -- | -- | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| IN8BIO, Inc. | 0.00 | -31.04m | 44.57m | 31.00 | -- | 2.49 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Clene Inc. | 620.00k | -48.81m | 45.08m | 82.00 | -- | 10.57 | -- | 72.71 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 45.18m | 75.00 | -- | 0.4994 | -- | 1.90 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Aligos Therapeutics Inc | 13.79m | -99.59m | 45.30m | 67.00 | -- | 0.764 | -- | 3.28 | -1.51 | -1.51 | 0.1796 | 0.7592 | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -- | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Kronos Bio Inc | 7.59m | -116.39m | 45.41m | 61.00 | -- | 0.3315 | -- | 5.99 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
Data as of May 24 2024. Currency figures normalised to Gain Therapeutics Inc's reporting currency: US Dollar USD
13.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Greenlight Capital, Inc.as of 31 Dec 2023 | 588.41k | 3.63% |
| DME Capital Management LPas of 31 Mar 2024 | 566.13k | 3.49% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 260.02k | 1.60% |
| RBC Capital Markets LLC (Investment Management)as of 31 Mar 2024 | 248.50k | 1.53% |
| Geode Capital Management LLCas of 31 Mar 2024 | 177.09k | 1.09% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 109.85k | 0.68% |
| CM Management LLCas of 31 Mar 2024 | 90.00k | 0.56% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 73.02k | 0.45% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 46.70k | 0.29% |
| Millennium Management LLCas of 31 Mar 2024 | 44.42k | 0.27% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
